AD			

Award Number: DAMD17-03-1-0153

TITLE: Polyphenols and Prostate Cancer Chemoprevention

PRINCIPAL INVESTIGATOR: Coral A. Lamartiniere, Ph.D.

CONTRACTING ORGANIZATION: University of Alabama at Birmingham

Birmingham, Alabama 35294

REPORT DATE: March 2004

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;

Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

### Form Approved REPORT DOCUMENTATION PAGE OMB No. 074-0188 Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503 1. AGENCY USE ONLY 2. REPORT DATE 3. REPORT TYPE AND DATES COVERED (Leave blank) March 2004 Annual (1 Mar 03-29 Feb 04) 4. TITLE AND SUBTITLE 5. FUNDING NUMBERS Polyphenols and Prostate Cancer Chemoprevention DAMD17-03-1-0153 6. AUTHOR(S) Coral A. Lamartiniere, Ph.D. 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION University of Alabama at Birmingham REPORT NUMBER Birmingham, Alabama 35294 E-Mail: Coral@uab.edu 9. SPONSORING / MONITORING 10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) **AGENCY REPORT NUMBER** U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABILITY STATEMENT 12b. DISTRIBUTION CODE Approved for Public Release; Distribution Unlimited 13. ABSTRACT (Maximum 200 Words) The polyphenols, catechin, (-)-epigallocatechin-3-gallate (EGCG), genistein and resveratrol, are associated with reduced incidences of prostate and breast cancers. The goal of this research is to investigate the potential of these 3 pure polyphenols, alone and in combination, to protect against prostate cancer in an animal model that spontaneously develops prostate cancer (TRAnsgenic Mouse Prostate adenocarcinoma (TRAMP)). In this manner, it may be possible to ingest moderate amount of each of these foods/chemicals, as opposed to mega amounts of one, and receive an additive or synergistic protective effect without adverse effects with possible elevated exposure. The specific aims are 1) to investigate the potential of genistein, EGCG and resveratrol, alone and in combination, to suppress the development of spontaneously developing prostate tumors and 2) to investigate the potential of genistein, EGCG and resveratrol to regulate sex steroid- and specific growth factorreceptor and ligand expression as mechanism of prostate cancer prevention. To date, the offspring were evaluated for transgene expression, and male TRAMP mice were subjected to these nutritional chemicals in AIN-76A diet or to control diet (AIN-76A), starting at 5 weeks postpartum. Each group contains 30 TRAMP males. Necropsy is scheduled for April – June 2004. Aim 2 has been initiated. 14. SUBJECT TERMS 15. NUMBER OF PAGES

Genistein, EGCG, Resveratrol, Prostate Cancer Chemoprevention, Mice

18. SECURITY CLASSIFICATION

Unclassified

OF THIS PAGE

OF REPORT

17. SECURITY CLASSIFICATION

Unclassified

20. LIMITATION OF ABSTRACT

Unlimited

16. PRICE CODE

19. SECURITY CLASSIFICATION

Unclassified

**OF ABSTRACT** 

# **Table of Contents**

Cover	1
SF 298	2
Contents	3
Introduction	4
Body	4
Key Research Accomplishments	5
Reportable Outcomes	5
Conclusions	5
References	
Appendices	

#### Introduction

Asians consuming a diet high in soy products have reduced incidence of clinically manifested prostate cancers. Likewise, Asians have a long history of drinking tea. Significant components of these two staples of the traditional Asian diet are the polyphenolic compounds. The primary polyphenols associated with prostate chemoprevention are the soy isoflavone, genistein, and the tea catechin, (-)-epigallocatechin-3-gallate (EGCG). Another polyphenol that has recently received attention as a cancer suppressor is resveratrol, a component of grapes. The goal of this research is to investigate the potential of these 3 pure polyphenols, alone and in combination, to protect against prostate cancer. In this manner, it may be possible to ingest moderate amount of each of these foods/chemicals, as opposed to mega amounts of one, and receive an additive or synergistic protective effect without adverse effects with possible elevated exposure.

#### **Body**

Aim 1) To investigate the potential of the polyphenols, genistein, EGCG and resveratrol, alone and in combination, to protect against prostate cancer. This is being evaluated in the <u>TRA</u>nsgenic <u>M</u>ouse Prostate adenocarcinoma (TRAMP) model that spontaneously develop prostate cancer. (Months 1-18)

Relying on preliminary data from mammary chemoprevention studies with genistein, EGCG and resveratrol in rats (an NIH supported study), where the low doses did not exert chemopreventive effects, we have concentrated on determining if single exposure to the proposed high doses of EGCG (0.06% in drinking water), resveratrol (625 mg/kg diet) and genistein (250 mg/kg diet), starting at 5 weeks of age, were going to be tolerated and result in suppressing prostate cancer development. C57BL/6 males and TRAMP females were bred and offspring have been produced. The offspring were evaluated for transgene expression, and male TRAMP mice were subjected to these nutritional chemicals in AIN-76A diet or to control diet (AIN-76A), starting at 5 weeks postpartum. Each group contains 30 TRAMP males. Necropsy is scheduled for April – June 2004. Following histopathological evaluation of the tumors by Dr. Isam Eltoum, we will decide if additional doses will be necessary. If these doses are appropriate for chemoprevention, we will initiate the combinational chemoprevention protocols.

Aim 2) To investigate the potential of genistein, EGCG and resveratrol to regulate sex steroid- and specific growth factor- receptor and ligand expression as mechanisms of prostate cancer prevention. From the dorsolateral prostates of mice exposed ± polyphenols we will investigate expression of the androgen receptor (AR), estrogen receptors (ERs), epidermal growth factor receptor (EGFR), transforming growth factor-alpha (TGF-alpha), epidermal growth factor (EGF), insulin-like growth factor-I (IGF-I), IGF binding protein-3 (IGFBP-3), and extracellular signaling regulating kinases-1 and 2 (ERK-1 and ERK-2). (Months 18-36).

We have actually initiated this study. Mice are being bred and the offspring are being evaluated for transgene expression. Realizing that 2 mice/sample are insufficient to produce enough protein to measure all of the proteins proposed by western blot analysis, we are producing 3 mice for each sample, 8 samples/group. After we obtain the data of the single treatments, we will set up the combinational treatments.

# **Key Research Accomplishments**

Except for the chemical treatments not having adverse effects on water and diet consumption, and on body weight, we have no data to report at this time.

# **Reportable Outcomes**

None at this time.

### Conclusion

Except for the chemical treatments not having adverse effects on water and diet consumption and on body weight, we have no conclusion to report at this time.